Abstract: Therapeutic peptides of the following sequence are disclosed: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, and optionally further comprising Xaa6, wherein Xaa represents an amino acid; Xaa3 is proline; and subscripts represent the positions of each amino acid in the peptide sequence starting from the amino terminus of said peptide extending to the C-terminus. A therapeutic peptide optionally includes a linker that cyclizes the peptide. Also described are methods of treating a neurodegenerative disorder and/or injury in a human subject in need of such treatment by administering to the subject a therapeutically effective amount of a therapeutic peptide as disclosed herein.

Abstract: Therapeutic peptides of the following sequence are disclosed: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, and optionally further comprising Xaa6, wherein Xaa represents an amino acid; Xaa3 is proline; and subscripts represent the positions of each amino acid in the peptide sequence starting from the amino terminus of said peptide extending to the C-terminus. A therapeutic peptide optionally includes a linker that cyclizes the peptide. Also described are methods of treating a neurodegenerative disorder and/or injury in a human subject in need of such treatment by administering to the subject a therapeutically effective amount of a therapeutic peptide as disclosed herein.

Abstract: Therapeutic peptides of the following sequence are disclosed: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, and optionally further comprising Xaa6, wherein Xaa represents an amino acid; Xaa3 is proline; and subscripts represent the positions of each amino acid in the peptide sequence starting from the amino terminus of said peptide extending to the C-terminus. A therapeutic peptide optionally includes a linker that cyclizes the peptide. Also described are methods of treating a neurodegenerative disorder and/or injury in a human subject in need of such treatment by administering to the subject a therapeutically effective amount of a therapeutic peptide as disclosed herein.

Abstract: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Abstract: A method of treating Parkinson's disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered directly to one or both putamen of a human in need of treatment thereof via convection-enhanced infusion using at least one implantable pump and at least one catheter. In one aspect of the present invention the GDNF is infused directly into one or both putamen through one or more indwelling intraparenchymal multiport brain catheters connected to one or more implantable pumps wherein the flow rate is pulsed.

Abstract: A method of treating Parkinson's disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered directly to one or both putamen of a human in need of treatment thereof via convection-enhanced infusion using at least one implantable pump and at least one catheter. In one aspect of the present invention the GDNF is infused directly into one or both putamen through one or more indwelling intraparenchymal mutitiport brain catheters connected to one or moreimplantable pumps wherein the flow rate is pulsed.

Abstract: A method of treating Parkinson's disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered directly to one or both putamen of a human in need of treatment thereof via convection-enhanced infusion using at least one implantable pump and at least one catheter. In one aspect of the present invention the GDNF is infused directly into one or both putamen through one or more indwelling intraparenchymal mutitiport brain catheters connected to one or moreimplantable pumps wherein the flow rate is pulsed.

Abstract: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Abstract: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Abstract: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Abstract: A method of treating Parkinson's disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered directly to one or both putamen of a human in need of treatment thereof. In one aspect of the present invention the GDNF is infused directly into one or both putamen through one or more indwelling intraparenchymal brain catheters connected to an implantable pump.